cyrilzakka/clinical-trials huggingface dataset:
Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

The central hypothesis is that daily dental xylitol wipes, in addition to current oral care practice, are effective at reducing BSI from oral organisms, and decreasing the incidence of gingivitis, oral plaque, and oral ulcerations after SCT.

Our long-term goal is to develop and disseminate clinically relevant, and easily adoptable strategies to prevent BSI and improve outcomes after SCT. The overall objective of this proposal is to identify a clinically effective strategy to prevent or reduce BSI secondary to bacterial translocation through oral injured mucosa .

Eligibility Criteria:
Inclusion Criteria:

* Patients of any age undergoing SCT.

Exclusion Criteria:

* Prior proton or photon radiation treatment for cancer of the oral cavity, head or neck; cranial boost in patients receiving total body irradiation; known history of allergy to xylitol; inability to use a mouth rinse or dental wipes.
The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension Messages

The researchers are aimed to investigate the early diagnosis of pulmonary nodule based on DNA, RNA, protein, metabolites through analyzing the serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and clinical characteristics.

By recruiting people with pulmonary nodules identified by CT scans, three groups are confirmed as the lung cancer group, the benign lung nodule group who are identified by pathological analysis, and the small lung nodule group that should be followed up. Then the serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Eligibility Criteria:
Inclusion Criteria:

For lung cancer groups

* (1) Patients diagnosed with lung cancer;
* (2) Clear diagnosis by pathological examination to determine pathological type;
* (3) Those aged 18-80 years old;
* (4) For patients with newly diagnosed lung cancer, CT confirmed that the size of primary lung cancer is ≤ 3 cm;
* (5) The patient or family member agrees to participate in the study and sign an informed consent form;
* (6) No other serious cardiopulmonary diseases. For lung nodule
* (1) Those aged 18-80 years;
* (2) CT clear lung nodule size ≤ 3cm;
* (3) 1-3cm pulmonary nodules confirmed by pathological diagnosis as non-lung cancer or other metastatic cancer patients or ≤1cm pulmonary nodules
* (4) The patient or family member agrees to participate in the study and sign an informed consent form;
* (5) No other serious cardiopulmonary diseases.

Exclusion Criteria:

* (1) Women who are breast-feeding, pregnant or preparing for pregnancy;
* (2) Those who are allergic to allergies and multiple drugs;
* (3) Combining severe primary diseases such as cardiovascular and cerebrovascular, liver, kidney, and hematopoietic system, as well as subjects with mental illness;
* (4) concurrently infected;
* (5) Those who participated in other clinical trials within three months.
Body Composition After Laparoscopic Gastrectomy for Gastric Cancer

Nutritional status including changes of body composition is one of the most important clinical determinants of outcome after gastrectomy for gastric cancer. Various type of gastric operations are widely used with favorable outcome in South Korea. It was reported that several advantages of laparoscopic gastrectomy are the prevention of overt weight loss and enhanced recovery of muscle mass at 6 months after surgery. But there have been no longitudinal studies evaluating changes in the body composition according to the different type of anastomosis of laparoscopic gastrectomy.

The purpose of this prospective study was to investigate changes in lipid indices associated with whole body composition during 1 year of follow-up after laparoscopic gastrectomy. Gastrectomy resulted in improved lipid indices and a reduction in body weight, fat and LBM. The HDL-Csignificantly increased in the non-obese group for 1 year after gastrectomy and the reduction of TG level was positively correlated with fat, especially with trunk fat.

* All patients will undergo a laparoscopic gastrectomy for their gastric cancer (proved to be stage I or II) or benign gastric neoplasm by preoperative screening diagnostic procedure. They will receive laparoscopic gastrectomy as follows: (1) wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) laparoscopic gastrectomy; (4 gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy.
* Pre-operative, 6 and 12 months post-operative body composition measurement will be performed on each patient. The whole body composition measurement will be assessed by Hologic 4500/A dual energy X-ray absorptiometry system. The software performs calculations of the differential attenuations of the two photon energies and present data of percentage of fat, fat mass (g), lean mass (g), bone mineral content (g), bone mineral density (g/cm2), and total mass (g).
* Laboratory analysis - There is a battery of labs that are ordered in both the pre-operative, 6 and 12 months post-operative time frame. These labs are ordered independent of the patient's participation in the study. These labs are ordered to evaluate and to assist management of the patient's medical comorbidities as well as to assess for adequate nutritional intake and balance.
* Queries on nutritional intake and exercise will be made at each post-operative appointment.

Eligibility Criteria:
Inclusion Criteria:

* Patient with gastric cancer or benign gastric neoplasm planning gastric operation
* Stage I and II patients by preoperative screening

Exclusion Criteria:

* Distant metastasis
* Severe comorbidity
* Malnourished state
* Inability of access to enteral feeding
Comparison of a Non Contact Vital Signs Application With Traditional Pulse Oximetry for Heart Rate Measurement

The investigators want to test the accuracy of the Smartphone application Darwin Edge rVSM in measuring heart rate, as compared to traditional pulsoxymetry. The intervention is to look at the smartphone camera for approximately 30 seconds, and after that to compare the heart rate value with that obtained with a recording by pulsoxymetry.

Participants undergoing a routine perianesthetic consultation at the preanesthetic clinic will be recruited. as a part of routine clinical assessment their heart rate is measured with pulsoxymetry, a non invasive device worn at the fingertip for about 1 minute. this measurement will be compared to the values for heart rate that can be obtaine with the ''Darwin Edge rVSM'' mobile application. this application can be installed on any smartphone. the participant is required to look into the smartphone camera for about 30 seconds. environmental and lighning conditions will be kept stable.

The investigators will do the measurements in 200 participants in order to obtaine values in a population characterized by a variety of phenotypes, in the perioperative setting.

Eligibility Criteria:
Inclusion Criteria:

* Men or women older than 18 years old presenting to the preanesthetic assessment clinic of Valais Hospital
* Subjects that have signed the informed consent form

Exclusion criteria:

* subjects with damaged/injured skin at the face
* Subjects unable to remain still for 30 seconds
Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.

The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the examination is performed, they begin the study medication while admitted at Dept. of Cardiology, Herlev Hospital, for cardiac monitoring.

Eligibility Criteria:
Inclusion Criteria:

* Patients with stable, chronic systolic heart failure
* T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal
* LVEF ≤ 45 % on prior echocardiography

Exclusion Criteria:

* Established thyroid illness
* Atrial fibrillation/flutter
* More than 20% ventricular extrasystoles
* Severe chronic obstructive lung disorder
* Pregnancy. Pregnancy testing will be done for fertile women
* Age \< 18 years
Additional Effects of Surface Electromyographic Biofeedback on Post Facilitation Stretching and Strengthening in Lower Crossed Syndrome;A Randomized Control Trial

This study is a randomised control trial and the purpose of this study is to determine the additional effects of surface electromyographic biofeedback on post facilitation stretching and strengthening in lower crossed syndrome.

.

Participants will be recruited into their respective groups using a coin toss method. Lower crossed syndrome will be assessed using the following tests:

Prone hip extension test Trunk flexion strength test Tightness in erector spinae Modified Thomas test

Eligibility Criteria:
Inclusion Criteria:

* Age 19-35 years
* Both genders
* Positive modified Thomas test
* Positive prone hip extension strength test
* Positive trunk flexion strength test
* Tight erector spinae
* BMI normal (18.5-24.9 Kg/m2)
* Local intermittent lumbar pain
* moderate pain (NPRS 3-7)
* Painless movement and activity
* Pain only produced by sustained loading in relevant position, which is then relieved on moving from that pos

Exclusion criteria:

* Acute flare of LBP
* Centralization and peripheralization of pain
* Signs of stenosis(leg symptoms when walking that are eased upon flexion)
* Pain due to repetitive movements
* Paresthesia/Numbness
* Structual deformity(Kyphosis, spondylosis, spondylolisthesis,scoliosis and joint contractures)
* Curve reversal
* Pregnancy
* Post surgery
* Degenerative and inflammatory spine diseases
Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour

Epidural analgesia for pain relief in labor may not be suitable for all patients, and intravenous patient controlled analgesia (IV PCA) with opioids offers the best alternative. The purpose of this study is to assess the effectiveness of two methods remifentanil administration in the form of either an infusion or PCA demand bolus (intravenous injection of a single dose over a short period of time). Currently, our hospital gives remifentanil by demand bolus, however it may be equally effective, with less side effects, to give the drug as an infusion.

The study will be conducted as a randomized trial with two arms: Group I- continuous infusion of remifentanil with stepwise increase in infusion rates and Group II- demand bolus only with stepwise increase in bolus dose, as per the patient's analgesic requirement. Visual analog scores will be the primary outcome. Maternal and fetal side effects will be recorded. The results of this study will determine the regimen that suits the patients needs for painless labor with high efficacy, less adverse effects and a higher patient satisfaction.

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Term pregnancy in labour with singleton fetus in cephalic presentation
* Patients requesting systemic analgesia
* Patients with contraindication for regional anesthesia without fetal compromise (coagulopathy, thrombocytopenia, refusal, etc.)

Exclusion Criteria:

* Refusal to sign written informed consent
* Inability to communicate in English
* Opioid dependence or addiction
* Patients on Methadone
* Allergy or hypersensitivity to remifentanil
* Fetal heart rate abnormalities
* Fetal congenital anomalies
An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

Ulcerative colitis (UC) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. The hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus.. This study will assess how effective upadacitinib is in treating UC within a Chinese population.

Upadacitinib is an approved drug for treating UC. Approximately 80 adult participants, who have been prescribed upadacitinib for UC by their physician in accordance with local label, will be enrolled in China.

Upadacitinib will be administered in accordance with the terms of the local marketing authorization, and treatment of participants will be determined solely by the investigator. Participants in the study will be followed for up to 1 year.

There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and only data which are routinely collected during a regular visit will be utilized for this study.


Eligibility Criteria:
Inclusion Criteria:

* Chinese participants meet the diagnosis of moderately to severely active Ulcerative colitis (UC)
* Participants prescribed upadacitinib at discretion of their treating physicians based on sufficient consideration of benefits/risks for patients per local label
* Participant must be an adult (≥ 18 years)
* Participant must provide written authorization to use personal and/or health data prior to the entry into the study

Exclusion Criteria:

* Participant participating in any interventional trials
* Participant with any contraindication to upadacitinib as listed on the local China label
* Participant unwilling or unable to comply with the study requirements, including completion of patient reported outcome questionnaires
Postoperative Renal Failure in Cardiac Surgery PMSF-PVC Gradient Study

Acute renal failure is a frequent and severe postoperative complication of cardiac surgery performed under extracorporeal circulation.

It is an independent risk factor for mortality and significantly increases the length of hospital stay.

The origin of renal insufficiency after extracorporeal circulation is multifactorial (long duration of extracorporeal circulation, hemodynamic instability per and post-extracorporeal circulation, prolonged hypotension, transfusion ...).

Nevertheless, an entirely different pathophysiological mechanism, though not recent, is less often mentioned but shows renewed interest. This is the concept of renal venous congestion which may be responsible for impaired renal function in the absence of cardiac dysfunction. Based on Guyton's circulatory model, the investigators approach this systemic venous hypertension through the measurement of the Pmsf-PVC gradient.


Eligibility Criteria:
Inclusion Criteria:

* age\> 18 years
* subject having signed an informed consent
* scheduled heart surgery:

  * Valve replacement
  * Coronary artery bypass

Exclusion Criteria:

* Any urgent surgery or redux
* Severe preoperative chronic renal failure (stage III) defined by GFR \<30ml / min
* Existence of rhythm disorders (permanent ACFA) or serious cardiac conduction disorders, patients with Pacemaker
* Preoperative alteration of left ventricular ejection fraction with LVEF \<40%
* Major haemodynamic instability with refractory shock defined by dobutamine ≥10μg / kg / min and / or norepinephrine ≥ 1μg / kg / min and / or epinephrine ≥ 0.2μg / kg / min.
* Intra-aortic versus assisted pelvic balloon
* Contraindication to femoral arterial catheterization
* Subject under the protection of justice, subject under guardianship or under tutorship
* Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject)
Outcome Analysis of the Oxford Partial Knee Arthroplasty

Prospectively monitor the patients receiving the Oxford Partial knee arthroplasty

Utilization of systematic outcome measurements and specific designated time frames to monitor patient satisfactions will assist in analysing this type of prosthesis and the post operative period. Data collected will be added to the compiled information from previous studies in relation to the Oxford knee.

Eligibility Criteria:
Inclusion Criteria:

* Patient Suitable for Knee Replacement

Exclusion Criteria:
Establishing a Standard for Peri-operative Implantable Cardioverter Defibrillator (ICD) Patient Education

An implantable cardioverter defibrillator (ICD) administers a shock to terminate potentially life-threatening cardiac arrhythmias. The device saves lives, but presents psychological challenges for patients. At present, there is a paucity of brief interventions for ICD patients designed for administration in a clinic setting that considers issues of cost, time, and available resources. The present study examined the impact of a brief cognitive behavioral (CBT) educational intervention on primary endpoints of patient acceptance and quality of life and secondary endpoints of depression and anxiety. It was hypothesized that the intervention would result in significant improvements primary and secondary endpoints for participants in the intervention group.


Eligibility Criteria:
Inclusion Criteria:

* 18+ years old
* literate
* newly implanted with an implantable cardioverter defibrillator (ICD)

Exclusion Criteria:

* documented neurological sequelae associated with CVA or dementia
* documented cognitive impairment
* reported illiteracy
* previously implanted ICD
Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients

The response of Continuous Erythropoietic Receptor Activator (CERA) with different dose interval and the survey for influence factors:

We aim to evaluate a better clinical response which can be achieved by different dosing interval of a fixed dose of CERA. We expect this study can determine the dosing schedule with better clinical response to CERA and identify the associated factors predicting the cost-effectiveness of CERA in maintenance hemodialysis (HD) patients in Taiwan.

We included HD patients with stable hematocrit (between 30\~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we measured and compared the erythropoietic response (hematocrit, hemoglobin), profiles of iron status as well as nutritional status and inflammatory markers among the study subjects every two months for a total of 6 months. Those who had bleeding or received surgery or blood transfusion were excluded.

Eligibility Criteria:
Inclusion Criteria:

* HD patients with stable hematocrit (between 30\~36%) under intravenous administration of CERA 100 μg once monthly for two months.

Exclusion Criteria:

* HD patients were excluded due to active bleeding (major trauma, gastric ulcer bleeding, or surgery), blood transfusion or administration of additional erythropoietic stimulating agent (ESA) other than CERA within the follow-up period during the study perod of 6 months. People who discontinued CERA as their ESA were also excluded.
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of the lower limbs.

For reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of the lower limbs will be compared with that of fondaparinux.


Eligibility Criteria:
Inclusion Criteria:

* Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs

Exclusion Criteria:

* Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period
* Patients who are at a significantly high risk for bleeding or thromboembolism
* Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy
* Patients who have evidence of hepatic function test abnormalities
Analysis of EPA® (a Food Intake Assessment Tool) as a Screening Test for Malnutrition in General Medicine

The main objective is to evaluate the sensitivity of the EPA® for screening for malnutrition in general medicine in adults.


Eligibility Criteria:
Inclusion Criteria:

* To be an adult,
* Consulting the principal investigator, a general practitioner in his activity of substitute doctor,
* During the inclusion period,
* Not opposed to participating in the study.

Exclusion Criteria:

* Patients benefiting from artificial nutrition,
* Patients with advanced dementia,
* Pregnant or postpartum women,
* Patients who do not understand or speak French,
* Patients treated with diuretics who have had a change in treatment dosage during the last 6 months,
* Patients for whom weight measurement is not possible in the office (wheelchair, disability ...),
* Patients who have already been included once,
* Patients who have had surgery for obesity,
* Major persons subject to legal protection (legal safeguards, guardianship, tutorship), persons deprived of their liberty, ...
Botox in the Healing of Surgical Wounds of the Neck

The investigators hypothesize that Botox A will reduce scarring and improve healing of surgical neck wounds.

Botulinum Toxin A is a toxin produced by the anaerobic bacterial species Clostridium botulinum. The toxin specifically inhibits release of the neurotransmitter Acetylcholine at synaptic junctions, thus preventing neuromuscular transmission, and inducing paralysis of the muscle.

Previous studies have indicated that tensile forces on the skin may affect the healing of a wound. These forces act against the immature collagen laid down during wound healing and may stimulate overgrowth, thereby contributing to the formation of hypertrophic scars or keloids.

Using botox to paralyse the underlying muscles may reduce the tensile force on the overlying skin, and thus reduce scar formation and promote healing. Botox has also been shown to affect the cell cycle distribution of fibroblasts derived from hypertrophic scars.

The objective of this study is to determine the effects of BTX-A in wound healing and the reduction of scar formation.

Patients undergoing a thyroidectomy or parathyroidectomy will be randomized to receive either BTX-A injections along the surgical site or placebo immediately following closure. All incisions will be sutured in a similar fashion. BTX-A or normal saline will then be injected along the platysma muscle. The patient and the surgeon will be blinded to the treatment arm. Photographs will be taken of the surgical site at 4 weeks and 6 months. The patient and two otolaryngologists will independently score the healing of the wound using a standardized scoring method. The scores be compared between the two surgeons to determine correspondence and interobserver reliability.

The scores of the two treatment arms will be compared to reveal the effect of BTX-A on wound healing.

Eligibility Criteria:
Inclusion Criteria:

* all patients referred to the ENT clinic for a thyroidectomy or parathyroidectomy

Exclusion Criteria:

* patients with missing information, including demographic information
* patients lost to follow up or have been followed for less than 6 months
* patients with known allergy to lidocaine
* patients in whom botox would be contraindicated in:
* known history of neuromuscular disorders (myasthenia gravis, amyotrophic lateral sclerosis, Eaton-Lambert syndrome)
* pregnant women
* known allergy to botox, albumin